Caris Life Sciences Inc.
CAI | NASDAQ
$32.91
-$1.42 (-4.14%)
Nov 2, 2026, 11:39 AM ET · Market open
Company Profile
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Key Executives
| Name | Position |
|---|---|
| David Dean Halbert | Chairman, Chief Executive Officer & Founder |
| Stephanie Thomas | Executive VP & Chief of Staff at Office of the CEO |
| Luke Power | Senior Vice President, Chief Financial Officer & Chief Accounting Officer |
| Valeriy Domenyuk | Senior Vice President & Chief Technology Officer |
| Brian J. Brille | Executive Vice Chairman & Executive Vice President |
| David Spetzler | President |
| J. Russel Denton | Senior Vice President, General Counsel & Secretary |
| Jeremy O'Brien | Senior Vice President of Human Resources & Chief Compliance Officer |
| Jon Mark Harmon | Senior Vice President & Chief Operations Officer |
| Milan Radovich | Senior Vice President & Chief Scientific Officer |
| Narendra Chokshi | Senior Vice President of Corporate Development |
Caris Life Sciences Inc.
| Country | United States |
| IPO Date | Jun 18, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,846 |
| CEO | David Dean Halbert |
Contact Details
750 West John Carpenter Freeway Irving,
Texas 75039 United States
Stock Details
| Ticker Symbol | CAI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002019410 |
| CUSIP Number | 142152107 |
| ISIN Number | US1421521071 |
| SIC Code | 7359 |
Recent News
- 5 days ago / zacks.comAnalysts Estimate Caris Life Sciences,?Inc. (CAI) to Report a Decline in Earnings: What to Look Out for
- 14 days ago / prnewswire.comCaris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer Detection
- 18 days ago / prnewswire.comCaris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
- 19 days ago / prnewswire.comCaris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026
- 1 month ago / investors.comIPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months
- 2 months ago / seekingalpha.comCaris Life Sciences: Diagnostics Growth With Room To Run
- 2 months ago / zacks.comCaris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?
- 2 months ago / prnewswire.comCaris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect
- 2 months ago / prnewswire.comCaris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer
- 2 months ago / proactiveinvestors.co.ukCaris Life Sciences study finds AI tool could guide pancreatic cancer treatment choice
Add to Watchlist
Select watchlists to add or remove CAI